PrenatalSAFE Test in London

PrenatalSafe is based on whole genome sequencing (WGS). WGS represents a cutting-edge approach in non-invasive prenatal testing (NIPT), delivering a thorough examination of an unborn baby’s genetic composition. This progressive method delves into the entirety of the genome, delivering an unmatched understanding of potential chromosomal irregularities and genetic disorders. Unlike the constraints linked to the Harmony test like types of NIPT, the prominence of whole genome sequencing has surged due to its extensive coverage and precision.

PrenatalSafe utilizes a remarkably efficient process requiring only a single blood tube for testing. This streamlined approach is possible due to the advanced technology and techniques the Lab employ. Through careful sample handling and sophisticated analysis methods, scientists can extract the necessary genetic information from just one blood sample, minimizing the inconvenience and discomfort associated with multiple blood collections. We have chosen this test due to our commitment to providing you with accurate and comprehensive results while ensuring your comfort.

Non-Invasive Prenatal Testing (NIPT), also known as Non-Invasive Prenatal Screening (NIPS), is an assessment method used to determine the likelihood of a baby being born with conditions like Down’s syndrome or other chromosomal anomalies or single gene disorders. NIPT relies on analyzing tiny DNA fragments from the baby’s placenta, referred to as ‘cell-free DNA’ or ‘cfDNA,’ which circulate in the bloodstream of pregnant mothers. This placental cfDNA is typically identical to the baby’s DNA, offering a means to identify certain chromosomal anomalies at an early stage without posing any risk to the baby.

It’s important to note that NIPT is a screening test, implying that it does not provide a definitive confirmation regarding whether the baby has Down’s syndrome or other tested chromosomal conditions. If the results indicate a positive outcome (indicating a high chance), additional invasive testing becomes necessary to obtain a conclusive diagnosis. However, it’s essential to understand that any invasive testing carries a slight risk of miscarriage.

Illumina, Inc, an American biotechnology company founded in 1998, specializes in producing high-throughput DNA sequencing systems, commonly called DNA sequencers. They have achieved this position of prominence by building on groundbreaking technology originally developed by the British DNA sequencing company Solexa, based in Cambridge, UK. In a significant move, Illumina acquired Solexa, merging the pioneering DNA analysis capabilities of Solexa with its own expertise.

As of 2021, Illumina commands an impressive 80% share of the global DNA sequencing market, establishing itself as a dominant force in the field. Their commitment to innovation and quality has made them a trusted name in the biotechnology industry.

Illumina’s extensive experience and reputation for producing high-quality equipment extend to noninvasive prenatal testing (NIPT) applications. Their advanced technology plays a pivotal role in ensuring accurate and reliable results in this critical area of healthcare. Our recommended NIPT provider PrenatalSafe based on Illumina’s biotechnology.

For noninvasive prenatal testing (NIPT), Illumina collaborates closely with Hamilton Robotics, enhancing the efficiency and reliability of their technology. This collaboration ensures that Illumina’s advanced sequencing systems, like the VeriSeq NIPT Solution v2, are seamlessly integrated with automated processes provided by Hamilton Robotics. This partnership contributes to the streamlined and high-quality NIPT services that laboratories like Eurofins PrenatalSafe can offer to healthcare professionals and expectant parents.

The Illumina VeriSeq NIPT Solution v2 is a highly advanced and specialized piece of equipment and software developed collaboratively by two prominent American biomedical companies, Illumina and Hamilton Robotics. This technology represents a significant advancement in prenatal testing and is vital in ensuring the accuracy and reliability of noninvasive prenatal testing (NIPT) results.

It’s important to understand that the Illumina VeriSeq NIPT Solution v2 is not a standalone test or a brand name in itself. Instead, it serves as the underlying technology that powers NIPT services provided by various healthcare providers and laboratories. These providers often use their own unique trade names for the tests they offer based on this technology.

For example, Eurofins, a well-established and reputable NIPT provider, has been utilizing the Illumina VeriSeq technology for many years to conduct their NIPT, which they market under the name “PrenatalSafe.” Eurofins’ extensive experience and track record with this equipment have contributed to their reputation.

The VeriSeq NIPT Solution v2 is a complete package for noninvasive prenatal testing (NIPT) using next-generation sequencing (NGS) technology. It includes reagents for DNA extraction, sample preparation, and sequencing. It has an onsite server for secure data storage and analysis and data analysis software capable of generating comprehensive qualitative NIPT results. This automated and reliable system offers rapid turnaround times (26 hours for the cycle), enabling laboratories to process up to 96 samples in approximately one day.

This Illumina NIPT solution provides highly accurate information about fetal chromosomal status as early as 10 weeks of gestation, using just a single maternal blood draw. It offers screening for aneuploidies in all autosomes, chromosomes X & Y, and identifies partial deletions and duplications larger than 7 Mb across the genome. We use this advanced technology for our SMART TEST. With its high sensitivity and specificity, NGS-based NIPT reduces the need for invasive procedures.

It’s important to note that while the Illumina VeriSeq NIPT Solution v2 is a valuable tool, the accuracy of NIPT tests relies on the laboratory’s expertise and accreditation. Specifically, ISO 15189 accreditation, like that offered by the United Kingdom Accreditation Service (UKAS), is a crucial indicator of quality and reliability.

If a lab has previously struggled with the performance of NIPT tests or lacks accreditation, trust in its results may be questioned. In our evaluation of UK labs using Illumina VeriSeq NIPT Solution v2, PrenatalSafe stands out as a strong choice. Located in the UK, they offer accessibility, accreditation, local expertise, and support in cases of abnormal results, making them a compelling option for accurate and trustworthy NIPT services.

It’s noteworthy that the Illumina VeriSeq NIPT Solution v2 has had such a significant impact on the noninvasive prenatal testing (NIPT) landscape in that it prompted TDL, a long-standing monopolistic provider of Harmony NIPT in the UK, to transition to the technology used by their competitor, Eurofins PrenatalSafe. This move underscores the remarkable capabilities and performance of the VeriSeq NIPT Solution v2.

While TDL may be in the process of adopting this new and advanced technology, it’s reasonable to anticipate that, with time and effort, they may achieve results similar to those demonstrated by Eurofins PrenatalSafe. This transition represents a commitment to providing improved NIPT services and underscores the continuous advancements in the field of prenatal testing.

Expectant parents can look forward to a more competitive landscape in the UK that drives innovation and ultimately benefits patients by offering access to advanced and reliable NIPT options.

That transition has since completed: TDL now runs its Illumina VeriSeq v2 assay in London under the name TDL VeriSeq V2, positioned as the successor to the Harmony test it withdrew in 2023. Like PrenatalSafe, it is a UK-analysed basic screen for Down’s (T21), Edwards’ (T18) and Patau’s (T13) syndromes with optional fetal sex, priced at £540 with our ultrasound scan and reporting in 2–4 working days.

It’s crucial for us that you understand the terminology we use for screening tests:

The detection rate is defined as the fraction of all patients who have the disease and are called positive by the screening test.

Positive Predictive Value or PPV is the proportion of the ‘true positives’ as a proportion of all positive results. As a practical example, the PrenatalSafe laboratory reports a PPV of around 99% for Down’s Syndrome in its own validation cohort.

It is important to understand that PPV is not fixed: it depends on how likely the condition was before testing (largely driven by maternal age and any prior screening result). In a general, lower-risk population the true PPV is materially lower — the cited meta-analysis (Taylor-Phillips et al.

, BMJ Open 2016) reports around 82% for Down’s syndrome, rising to about 91% in higher-risk pregnancies. In other words, a proportion of ‘High Probability’ results will be ‘false positives’, where the test returns a ‘High Probability’ result for a fetus that does not in fact have Down’s Syndrome.

That’s why, for every High Probability result, we would refer the patient for a diagnostic test such as CVS or Amniocentesis to verify the results.

There has been confusion about certain aspects of NIPT in the past – please see this notice. If any of the above is still unclear to you, please contact us via email or phone, and our friendly staff will be happy to run you through the characteristics of the test.

We wrote a special blog post about understanding the statistics of the NIPT test. If you would like to find out more, click here.

PrenatalSafe uses advanced genomics technology and a proprietary test algorithm. This NIPT offers secure performance for common chromosomal anomalies such as Down’s (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes. The great things about PrenatalSafe are that it needs a small amount of maternal blood (just one tube) and has low no-call rates (less than 2%).

PrenatalSafe works in situation of ‘vanished’ twin syndrome where other NIPT options are not applicable. Moreover, it offers a high level of accuracy when it comes to optional determining the gender of the baby.

Currently, we consider PrenatalSafe as the best option for NIPT in London, because it provides advanced technology, low no-call results, and a short turnaround time (the lab is UK based). PrenatalSafe can be considered the best alternative to the Harmony test with only the limitation of limited experience with this test in London.

The PrenatalSafe test covers the three most common chromosomal conditions screened for in early pregnancy: Down’s syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13). Determining your baby’s sex is available as an optional extra. It is a screening test rather than a diagnostic one, so it tells us the chance of a condition being present, not a definitive yes or no.

At London Pregnancy Clinic, we pair PrenatalSafe with an expert ultrasound — ideally our 10 Week Scan — so genetic screening and an early structural assessment happen at one appointment. If you would like a wider panel covering sex chromosome anomalies and microdeletions, our SMART Test is the extended option. For a high-chance result, a clinician will explain your next steps, which may include diagnostic testing.

• Down’s syndrome (T21)
• Edwards syndrome (T18)
• Patau syndrome (T13)
• fetal sexing (optional)

The newly established UK lab in Guilford closely mirrors the primary Eurofins Genoma Lab situated in Rome, Italy. It adopts identical equipment, bioinformatics processes, and protocols as the central lab, which is renowned as the foremost NIPT provider in Europe. While the UK Lab’s services have only recently commenced, there is currently no available data concerning its performance. However, there is no compelling rationale to anticipate any variance in performance from the UK Lab.

For reference, the laboratory’s own reported performance figures from Eurofins Genoma, derived from a sample of 71,883 pregnancies, are set out below. These are the manufacturer’s validation figures; specificity and negative predictive values approaching 100% should be read as ‘very high’ rather than absolute, and PrenatalSafe remains a screening test — a ‘High Probability’ result always requires diagnostic confirmation by CVS or amniocentesis.

For Down’s syndrome (T21):

For Edwards syndrome (T18):

For Patau’s syndrome (T13):

• Sensitivity 99.54%
• Specificity 100%
• Positive predictive value 99.32%
• Negative predictive value 100%
• Sensitivity 100%
• Specificity 100%
• Positive predictive value 98.94%
• Negative predictive value 100%
• Sensitivity 100%
• Specificity 99.99%
• Positive predictive value 82.22%
• Negative predictive value 100%

Our basic PrenatalSafe panel does not include sex chromosome anomalies (SCA) or microdeletions.

For our extended NIPT package, which includes SCA and microdeletions please refer to SMART Test NIPT.

The main advantages of NIPT are related to Down’s syndrome (T21) screening.

They are:

• early testing from 10 weeks
• high negative predictive value for T21
• high detection rate for T21
• low false-positive rate for T21

As with any screening test NIPT has some disadvantages.

Here there are the most significant NIPT limitations:

• relatively high cost of the cfDNA tests
• whilst a very sensitive screening test, it is not diagnostic
• cannot detect ANY physical (structural) anomaly
• limited effectiveness for babies that have increased nuchal translucency (NT) thickness or physical (structural) anomaly
• failure to return a result in up to 6.5% of women (‘no-call’ results), which is more common for Harmony Test

The ideal timing for your PrenatalSafe NIPT is at 10 weeks due to the following reasons:

• Seeking early reassurance about Down’s syndrome is a priority for you.
• At 10 weeks, we conduct the earliest fetal structural anomaly scan, which effectively rules out severe non-chromosomal defects.
• Opting for the test at this point allows ample time for a retest if the NIPT yields a no-call result, and you can also pursue alternative screening for Down’s syndrome through the Combined Test.
• In the event of a high-chance NIPT outcome, you have the option to undergo CVS (invasive testing) to promptly confirm or rule out any chromosomal issues, typically around 11-12 weeks.
• Should our 10 Week Scan reveal any abnormal findings, we’ll ensure a swift referral to the Fetal Medicine Unit, saving you time and resources by avoiding inappropriate NIPT testing. It’s important to note that NIPT is not a suitable test for cases involving structural fetal anomalies.
• PrenatalSafe due to its advanced technology has a low no-call results rate even at 10 weeks

Initially, our Fetal Medicine Doctor or Advanced Sonographer will conduct a thorough anatomical assessment of the baby, focusing on identifying any structural anomalies and collecting measurements for the NIPT test.

Once the clinician confirms the baby’s normal structural examination, they will provide a consultation about the NIPT. During this consultation, you’ll have the opportunity to ask questions and gain insights into every aspect of the test. Our team will also assist you in selecting the most appropriate NIPT tailored to your specific needs.

Subsequently, our friendly phlebotomist will collect a small blood sample (just one tube!) from your arm, similar to routine blood tests elsewhere.

Following the collection of blood samples, our dedicated staff will process them and promptly send them to the laboratory. After your appointment, all that remains is to await a call from our team.

Ultrasound plays an indispensable role in the comprehensive assessment of fetal health. To ensure accurate results, the laboratory necessitates confirmation of viability and gestational age from the clinic submitting each NIPT.

While NIPT excels as a screening test for three chromosomal anomalies, it is important to acknowledge its limitation in detecting structural anomalies such as heart or brain defects. These anomalies, often more prevalent and serious than Down’s Syndrome, cannot be identified through NIPT.

At the London Pregnancy Clinic, we specialize in the early identification of fetal anomalies, particularly focusing on the fetal heart and brain. Our expertise allows us to detect some of the most severe fetal anomalies as early as the 10th week of pregnancy. This commitment to early detection and specialized care sets us apart in ensuring the best possible outcomes for you and your baby’s health.

Visit our Scans Page to find out which scan you will be having along with NIPT. Generally, we believe that our 10 Weeks Scan is the best option.

We highly recommend undergoing the NIPT in conjunction with our comprehensive early anomaly scan, the 10 Weeks Scan, at the earliest opportunity – ideally at 10 weeks into your pregnancy. Detecting chromosomal or structural anomalies early provides greater flexibility in managing these conditions throughout your pregnancy. In the event of a sample failure, there’s ample time for a redraw without causing delays.

If you’re uncertain about the exact stage of your pregnancy, we urge you to consider our Viability Scan at around 7-8 weeks. This scan helps determine your pregnancy’s age, enabling us to arrange the earliest possible NIPT appointment for you.

If you choose not to undergo the Viability Scan, please allow a few days after reaching the 10-week mark to prevent the need for repeat appointments for blood collection. Additionally, by coming too early, you might miss out on the benefits of the 10 Weeks Scan, as your baby might be too young for a proper early anomaly assessment.

In theory, NIPT can be conducted from 10 to 40 weeks, but it’s strongly advised to opt for the test in the first trimester. This is because pregnancy management options become limited in the second trimester.

Yes, you can. Panorama AI is the only NIPT that works from 9 weeks. Please note that in this case structural assessment of the baby by ultrasound can be limited and we will be unable to screen for some very serious conditions like holoprosencephaly or spina bifida. If you wish to have NIPT before 10 weeks, please consider scanning from 9 weeks 4 days.

PrenatalSafe and Harmony do not work at 9 weeks.

The PrenatalSafe Test is not validated and can not be used for use in pregnancies with:

Please note that all types of IVF pregnancies are eligible for PrenatalSafe Test

• a history of or active malignancy
• a pregnancy with triplets, quadruplets or higher order
• a history of bone marrow or organ transplants
• mosaicism for the parents
• maternal aneuploidy (chromosomal abnormality)

No, we think it is outdated approach and the best way is to perform both 10 Weeks Anomaly Scan and NIPT at 9-10-11 weeks. The benefit of this approach is that the tests are performed as early as technically possible.

Understandably it will be impossible to visualise some fetal structures and organs at 10 weeks and some structural anomalies will be undiagnosed at this very early stage. Keeping this in mind, we recommend to perform our Early Fetal Scan at 15-16 weeks for further reassurance and exclusion of majority severe structural anomalies.

Learn more about our Early Pregnancy Scans.

Yes, PrenatalSafe or UNITY only.

Vanishing twin is a situation with twin pregnancies when the embryo or fetus in one of the sacs fails to develop or dies at the early stages of pregnancy. Interpretation of NIPT in the case of vanishing twin phenomenon is complicated due to contamination of the sample by DNA of non developing twin pregnancy. Harmony, KNOVA and Panorama NIPT cannot be used this situation.

However, we have a specific solution for pregnancies affected by this rare condition: PrenatalSafe Test, which can be used in the cases of vanishing twin phenomenon. This advanced non-invasive screening can be performed, but it’s important to wait at least five weeks after the vanishing twin is detected to ensure reliable results.

Turnaround time of the PrenatalSafe Test in London is fast – about 2-4 working days. It is better than the previously used Harmony Test by TDL.

A specialized medical courier service securely collects the sample from our clinic to Eurofins Lab in Guilford.

The Guilford Lab uses an advanced, fully automated VeriSeq whole-genome sequencing device by Illumina. An efficient workflow allows a sample to report in 26 hours. The dedicated bioinformatics algorithm calculates the probability of chromosomal anomalies and, after validation, the results are sent to us for further reporting to our patients.

After your scan appointment, you will be provided with a comprehensive scan report generated by our medical experts. This report will be available in both printed format and as a PDF, delivered securely through our cloud platform, Tricefy.

Upon receiving the NIPT test results from the lab, our clinicians will review and authorize them. Following this review, a member of our approachable clinical team will reach out to you over the phone to explain the implications of the test results. Subsequently, we will share an electronic version of the results with you via Tricefy for your reference.

In case the NIPT result is high chance for Down syndrome or other conditions our doctor will contact you and explain the further steps we advise to take. We will most likely arrange a referral to your NHS Fetal Medicine Unit for further counselling and possible diagnostic test such as CVS or amniocentesis.

Alternatively we can refer you to private Fetal Medicine Consultant (consultation cost is not included in our service).

Although the PrenatalSafe Test is very accurate, around 0.7% (data of Eurofins Genoma) of positive high chance for Downs syndrome results are false and the baby does not in fact have Down’s syndrome.

Biological factors with the potential to cause discordance between cfDNA results and baby’s genetic status include uncommon conditions like confined placental mosaicism, fetal mosaicism, maternal chromosome changes, and the presence of an unrecognised, nonviable (or viable) twin.

Most pregnant women receive complete results from cfDNA testing, indicating either a high or low probability for aneuploidy.

In about <2% of cases, we will need to contact you without giving you a test result and ask to come for an additional sample of blood or to give us more information about your pregnancy or medical history. There will be no extra cost for additional blood test.

It is because, in a small proportion of blood specimens submitted after 10 weeks gestation, there is an insufficient amount of the baby’s cfDNA. This situation is called a low fetal fraction. The chance of having a low fetal fraction gets higher with increased maternal body weight. There are other rare factors making NIPT results inconclusive.

In the case of PrenatalSafe Test no-call results on repeated samples (0.5% probability), we will discuss with you options of alternative screening and/or referral for diagnostic testing if you either decline a second attempt at NIPT or do not receive a result after two attempts.

There are two main types of NIPT: basic and extended. The basic NIPT (like Harmony Test or PrentalSafe 3UK) primarily checks for common chromosomal syndromes such as Down, Edwards, and Patau syndromes, and can optionally determine the sex of the baby. On the other hand, extended or advanced NIPT (Panorama Test, PrenatalSafe Complete Plus and UNITY) can screen for a larger number of fetal genetic conditions, including rare syndromes, and can even assess the fetal blood group.

Different NIPT companies offer both basic and extended options, but the challenge lies in the variability of screening panels across providers. Each test may cover different genetic conditions and syndromes, depending on the genetic technology used by the biogenetic companies. This can be confusing for parents who are trying to make an informed decision about which test is best for their specific needs.

As a responsible and advanced pregnancy care clinic, we have carefully selected the best NIPT options currently available on the market. We have considered factors such as accuracy, coverage of genetic conditions, and reliability. Our aim is to provide parents with the most reliable and comprehensive information to assist them in choosing the right NIPT for their pregnancy.

London Pregnancy Clinic, a pioneering authority in expert ultrasound and NIPT, proudly introduces the Smart Test (NIPT). This advanced package seamlessly integrates cutting-edge ultrasound technology with the most sophisticated NIPT available. It offers comprehensive screening for Down syndrome, as well as approximately 100 severe rare diseases. The Smart Test is the ultimate choice for parents who seek extensive insights into their unborn babies’ health and genetic profile.

Please see below for the list of the best NIPT options, carefully selected by our team based on strict criteria that address different patients’ needs. We understand that every pregnancy is unique, and we are committed to providing the best possible care to ensure the health and well-being of both mother and baby.

Basic NIPT options: T21, T18, T13 screening, fetal sex (optional) performed in the UK with short turnaround time:

Please find a comparison table between the tests below.

• Harmony Test: very popular but outdated NIPT, provides robust performance, however suffers from high number of no call results (around 6.5% test failures, per our 2022–2023 internal audit). Not very accurate for fetal sexing. Expensive, considering its unsophisticated nature.
• PrenatalSafe (best choice) uses advanced genomics technology and a proprietary test algorithm. This NIPT offers fast and secure performance, needs a small amount of maternal blood, has low no-call rates (less than 2%) and works for ‘vanished’ twin syndrome.

GeneSafe is an advanced form of non-invasive prenatal testing (NIPT) specifically designed for the screening of single gene disorders. This innovative approach targets rare diseases like Noonan syndrome, cystic fibrosis, or achondroplasia, among others.

GeneSafe is performed by the same biotechnological company, Eurofins, which offers PrenatalSafe.

Unlike traditional NIPT, which focuses primarily on common chromosomal anomalies, GeneSafe’s specialized methodology allows for the detection of specific single gene disorders. This advancement in technology offers expecting parents the ability to assess the risk of these less common genetic conditions during pregnancy without the need for invasive procedures.

Please note that the specific details, availability, and accuracy of GeneSafe may vary based on the latest medical developments and research. It’s recommended to consult with medical professionals or relevant sources for the most accurate and up-to-date information about this specific NIPT technology.

PrenatalSafe® Complete Plus is one of the most comprehensive non-invasive prenatal tests (NIPTs) currently available in Europe, developed by Eurofins Genoma in Rome. It goes far beyond standard NIPT by screening for a broad range of rare genetic and chromosomal conditions—making it particularly valuable for parents seeking detailed early insight into their baby’s health.

Extensive Screening: It tests for:

• 22 chromosomal aneuploidies, including Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13).
• Sex chromosome anomalies like Turner syndrome (monosomy X).
• Rare chromosomal deletions and duplications smaller than 7 Mb.
• Nine clinically significant microdeletions, such as DiGeorge syndrome.
• Forty-four genetic syndromes, including Noonan syndrome.
• Five monogenic disorders, including cystic fibrosis.
• Fetal sex determination (optional).
• Cutting-edge Technology: Unlike traditional NIPTs that focus mainly on trisomies, this test uses advanced genomic technology to identify structural and single-gene defects with high precision.
• Integrated with Ultrasound at LPC: At London Pregnancy Clinic, the test is offered with an expert ultrasound scan—providing a truly holistic view of early fetal development as early as 10 weeks.

The Harmony test, an essential non-invasive prenatal screening for common chromosomal syndromes, has garnered a reputation as the first NIPT option introduced in London over a decade ago. Despite its demonstrated accuracy in detecting Down syndrome, it is crucial to underscore its significant drawbacks.

Notably, the test exhibits a high rate of inconclusive results, with a failure rate of 6.5%, according to our internal audit conducted between 2022 and 2023. This failure rate is particularly pronounced when the test is performed early in pregnancy.

The statistical performance metrics of the Harmony Test fall short when compared to the more advanced tests of the new generation, such as PrenatalSafe or Panorama tests.

In conclusion, the Harmony test’s reputation for reliability is overshadowed by its substantial shortcomings.

In the current landscape, more advanced and superior NIPT options are available in London and the UK. All our other NIPT options: PrenatalSafe, Panorama Test, and UNITY, perform better.

Our team of experts is dedicated to guiding you through this decision-making process and recommending the most optimal NIPT option tailored to your individual circumstances.

The PrenatalSafe NIPT offers several distinct advantages when compared to other NIPT providers:

But, to keep it accurate, here’s a little thing to consider:

• Uses cutting-edge technology
• Provides reliable Down’s syndrome screening
• Requires a minimal amount of maternal blood
• Provides rapid results
• Exhibits low rates of inconclusive outcomes
• Serves as a superior alternative to the Harmony Test
• Applicable even in cases of vanishing twin syndrome
• Holds a strong reputation in Europe
• Limited experience using the test in London

The PrenatalSafe can only be done from a gestational age of 10 weeks, while Panorama NIPT can be done from 9 weeks. TDL/Natera do not accept any blood samples for patients below that Gestational Age. We recommend to wait until a gestational age of 10 weeks + 2 days (9+4 for Panorama) to perform the Harmony/Panorama Scan to avoid having to come in more than once.

In case you booked for Panorama / PrenatalSafe Scan, but the ultrasound scan indicated a GA below 9/10 weeks (respectively), we will have to rearrange for you to come in at a later date for an additional cost of £50 to cover for our staffing cost.

In case of an initial No-Call result from the test (around 2–3% of first-pass cases; the residual no-call rate after a repeat sample is about 0.5%), we will be happy to schedule another time to draw a further blood sample free of charge. In case of a second No-Call result, we will refund the NIPT portion of the appointment charge as per below.

There is no reimbursement for inconclusive fetal sex results. In those rare cases we will offer you anatomy and gender scan for reduced cost and will discuss the findings and need for further referrals.

Yes. With our partner Jeen Health, you can book PrenatalSafe 3 NIPT from anywhere in the UK.

Your pregnancy scan is reviewed first to ensure NIPT is suitable, followed by a 20-minute consultation with a genetic counsellor.

Blood collection options include local arrangements, a visit to our London clinics, or a home visit nationwide (+£65). Your test kit arrives by next-day delivery, and results are sent securely online.

Available across the UK, including Manchester, Leeds and Glasgow.

Not through London Pregnancy Clinic — every NIPT we offer includes an expert ultrasound scan. The scan confirms your pregnancy is viable, dates it accurately and checks it is suitable for testing, which is why we do not offer the blood test on its own.

If you cannot get to our London clinic, our partner Jeen Health offers NIPT across the UK, including PrenatalSAFE. You will need to provide proof of a pregnancy scan taken within the last 7 days before your blood sample is taken.